Review Article

Levothyroxine Treatment in Pregnancy: Indications, Efficacy, and Therapeutic Regimen

Joanna Klubo-Gwiazdzinska,1,2 Kenneth D. Burman,1,2 Douglas Van Nostrand,3 and Leonard Wartofsky1,2

1 Section of Endocrinology, Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA
2 Division of Endocrinology and Medicine, Georgetown University Hospital, Washington, DC 20007, USA
3 Nuclear Medicine Division, Washington Hospital Center, Washington, DC 20010, USA

Correspondence should be addressed to Leonard Wartofsky, leonard.wartofsky@medstar.net

Received 1 March 2011; Revised 30 May 2011; Accepted 30 May 2011

Academic Editor: Roberto Negro

Copyright © 2011 Joanna Klubo-Gwiazdzinska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prevalence of overt and subclinical hypothyroidism during pregnancy is estimated to be 0.3–0.5% and 2–3%, respectively. Thyroid autoantibodies are found in 5–18% of women in the childbearing age. The aim of this review is to underscore the clinical significance of these findings on the health of both the mother and her offspring. Methods of evaluation of thyroid function tests (TFTs) during pregnancy are described as are the threshold values for the diagnosis of overt and subclinical hypothyroidism or hypothyroxinemia. Anticipated differences in TFTs in iodine-sufficient and iodine-deficient areas are discussed and data are provided on potential complications of hypothyroidism/hypothyroxinemia and autoimmune thyroid disease during pregnancy and adverse effects for the offspring. The beneficial effects of levothyroxine therapy on pregnancy outcomes and offspring development are discussed with a proposed treatment regimen and follow up strategy.

1. Introduction

During normal gestation, thyroid hormone production is augmented in order to meet the increased physiologic demands of the growing fetal placental unit. Alterations in thyroid function with pregnancy are derived via several mechanisms. Notably, there is an increase in serum estrogen levels during the first half of gestation up to 500–1000 pg/mL, resulting in upregulation by two- or threefold of hepatic production of thyroxine binding globulin (TBG) [1, 2]. The increased TBG levels alter the equilibrium between bound and free thyroxine (FT4) causing a temporary reduction in FT4 that in turn leads to increased thyrotropin (TSH) stimulation of the thyroid gland and physiologic restoration of FT4 at the cost of higher serum total T4 (TT4) levels. A second factor is the increased placental production of human chorionic gonadotropin (hCG), reaching a peak of approximately 50,000–75,000 IU/L at 8–11 weeks. This is significant because of the direct stimulatory effect of hCG on thyrocytes that is mediated through binding to the TSH receptor. Yet another issue is related to the increased need for iodine in pregnancy that is required to fuel the increases in thyroid hormone synthesis and compounded by the loss of iodine due to enhanced renal clearance [3, 4]. Therefore, the recommended average iodine intake during the pregnancy is between 250 and 500 ug/d [5, 6]. A final factor is the presence of placental iodothyronine deiodinase type III which alters the metabolism, distribution, and availability of T4 for both mother and fetus [4].

The prevalence of hypothyroidism during pregnancy is estimated to be 0.3–0.5% for overt hypothyroidism (OH) and 2-3% for subclinical hypothyroidism (SH). Thyroid autoantibodies are found in 5–18% of women in the childbearing age, and chronic autoimmune thyroiditis (AITD) is the main cause of hypothyroidism during pregnancy in iodide sufficient areas [7–9]. However, on a worldwide basis the most important cause of thyroid insufficiency remains iodine deficiency [10].

In view of the frequency of either OH or SH during pregnancy and the associated altered physiology, several questions face clinicians managing subjects with suspected thyroid dysfunction during pregnancy including (1) what
are the threshold values for the diagnosis of overt hypothyroidism (OH), subclinical hypothyroidism (SH), or hypothyroxinemia during the pregnancy? (2) Is the interpretation of thyroid function tests different in iodine-sufficient than in iodine-deficient areas? (3) What are the complications of hypothyroidism/hypothyroxinemia and autoimmune thyroid disease during the pregnancy? (4) Is levothyroxine therapy beneficial and effective in regard to improved outcomes and reduced complications associated with pregnancy and delivery? (5) How to select the patients for whom the treatment may be beneficial? (6) What is the appropriate treatment regimen and what are target thyroid function test values and how often should they be monitored? The aim of this paper is to address all of the above mentioned questions.

2. Methods

We have searched PubMed database from January 1970 to January 2011 for the articles written in English using the following keywords: “pregnancy and thyroid function”, “pregnancy and hypothyroidism”, “pregnancy and subclinical hypothyroidism”, “pregnancy and hypothyroxinemia”, “pregnancy and levothyroxine treatment”, “pregnancy and iodine deficiency”, “offspring complications and hypothyroidism”, “offspring complications and hypothyroxinemia” and “offspring complications and iodine deficiency”. We have included retrospective and prospective observational studies, clinical trials, meta-analyses, review papers, and guidelines published in the indexed journals.

2.1. What are the Threshold Values for the Diagnosis of Overt Hypothyroidism (OH), Subclinical Hypothyroidism (SH), or Hypothyroxinemia during the Pregnancy?

Establishment of reference ranges for thyroid function tests during pregnancy has been problematic due to variables based upon age, smoking status, ethnicity, BMI, iodine nutritional status, and the presence of latent or overt autoimmune thyroid disease [8,11].

Interpretation of any given value for FT4 or TSH should take into account the possible differences between population based reference ranges of thyroid function tests and a given patient’s narrower individual reference range. Based on data from 877 pregnant women, Shields et al. suggested that an individual’s level of TSH is associated with variation in the PDE8B gene with AA genotypic women being more likely to have elevated TSH concentrations (>4.21 mIU/L) compared to women with AG or GG genotypes (9.6 versus 3.5%, P < 0.0004). This observation was independent of the presence or absence of autoimmune thyroid disease (AITD) [12].

2.1.1. Normal Absolute Values and Optimal Methods for Assessment of Thyroid Function during Pregnancy

TSH. TSH is the single best indicator of insufficient thyroid hormone due to primary hypothyroidism [6]. However, there is a necessity for the trimester-specific reference range for TSH in each laboratory or at least each country/region in order to properly interpret the thyroid function tests.

Guidelines for diagnosis developed by the Endocrine Society and endorsed by the American Thyroid Association in 2007 recommend that TSH values should be <2.5 mIU/L in the first trimester and <3 mIU/L in the second and third trimester [6]. Data supporting this recommendation were derived from observations of the consistency in TSH ranges for first-trimester thyroperoxidase antibody-negative women, with a consensus centering around a lower limit of normal of 0.04 and upper range of normal of 2.5 mIU/L. It is worthwhile to underscore that this reference range was not significantly different between various populations. In a prospective study of 343 Chinese women, Panesar et al. [13] noted a normative range for first-trimester TSH levels of 0.03–2.3 mIU/L, which did not differ significantly from the range of 0.02–2.15 mIU/L established by Gilbert et al. [14] in 1817 Australian women between 9 and 13 weeks of gestation. A somewhat wider range and higher upper limit was seen by Pearce et al. [15] of 0.04–3.6 mIU/L in 585 thyroid antibody-negative women before 14 wks gestation, and by Stricker et al. [16] after screening 783 thyroid antibody-negative women in Switzerland (TSH 0.08–2.83 mIU/L). Männistö et al. based on a large (n = 9362) prospective population-based cohort from Northern Finland without AITD and with sufficient iodine intake reported a TSH reference range of 0.07 to 3.1 in the first trimester and up to 3.5 mIU/L in the second trimester. Moreover, they also observed that thyroid hormone levels are affected by BMI with higher TSH and FT3 and lower FT4 concentrations observed in obese women [11].

FT4, FT3. Although equilibrium dialysis and mass spectrometry/gas chromatography are the gold standards and are the most reliable methods of measurement of both FT4 and FT3 concentrations, these methods are too technically complex and expensive for routine use. Consequently, most FT4 testing in clinical laboratories is based on two-step or labeled antibody methodology, which is sensitive to abnormal TBG levels and liable to error [17,18]. There is a need for a method-specific, trimester-specific, and possibly population-specific FT4 reference range. Männistö et al. addressed this question for the anti-TPO negative and iodine sufficient Caucasian population, documenting that FT4 measured with chemiluminescent immunoassay increases slightly during early pregnancy and then decreases with the reference ranging between 11 and 22 pmol/L. Reference intervals for FT3 in the same study were stable during the pregnancy and ranged from 3.4 to 7 pmol/L [11]. However, Lee et al. documented that FT4 measured by two different immunometric assays diverges so significantly during the second and third trimesters that the vast majority of women would be diagnosed incorrectly as hypothyroxinemic by laboratory criteria alone. Each specific immunoassay needs to have normals and abnormals determined for the pregnant state, or immunoassays may underestimate FT4 [19].

TT4. The TT4 increase in pregnancy is more predictable than alterations in FT4, being generally 1.5 times
nonpregnant levels which is primarily related to increases in serum TBG as described above. Many studies have shown remarkably consistent ranges for T4 throughout pregnancy—approximately 143–158% of nonpregnant values. Adjusting the TT4 in pregnancy by a factor of 1.5 compared with nonpregnant reference ranges is a good reflection of TT4 [19]. Therefore, some authors advocate the use of TT4 in preference to FT4 for the evaluation and management of pregnant patients [20]. The Endocrine Society Guidelines as well as Laboratory Medicine Practice Guidelines advocate a TT4 cutoff of 100 nmol/L as appropriate for detecting a low FT4 state in pregnancy [6, 20].

**FT4 Index.** The free thyroxine index (FT4I) is measured as total T4 mathematically corrected for thyroxine binding globulin (TBG). FT4I is calculated by dividing TT4 by the thyroid hormone-binding ratio—the estimate of TBG. Changes in FT4I are consistent with the expected effects of TBG and hCG during pregnancy with a physiologic increase in the first trimester with normalization to nonpregnant levels in the second and third trimesters. This pattern of change during pregnancy corresponds to that described using the gold standard FT4 methods of equilibrium dialysis and tandem mass spectrometry [19].

To summarize, the FT4I index or the TT4 adjusted for pregnancy are reliable methods of estimating free thyroxine status in pregnancy.

2.2. Is the Interpretation of Thyroid Function Tests Different in Iodine-Sufficient than in Iodine-Deficient Areas?

Approximately 1.9 billion individuals, including 285 million school-aged children, are estimated to have inadequate iodine nutrition. Severe iodine deficiency in pregnancy can cause hypothyroidism, poor pregnancy outcome, cretinism, and irreversible mental retardation. Mild-to-moderate iodine deficiency in utero and in childhood may result in less severe learning disability, poor growth, and diffuse goiter [21]. It has been also suggested that even mild iodine deficiency may be associated with attention deficit and hyperactivity disorders in offspring [22].

The prevalence of iodine deficiency is lowest in the Americas (10.1%) and highest in Europe (59.9%) [23]. The thyroid gland responds to iodine deficiency through regulatory mechanisms that include decreased synthesis and secretion of T4 in favor of T3. In the case of mild to moderate iodine deficiency during the pregnancy, the circulating T3 levels remain normal or even increase slightly and circulating TSH levels do not increase. So the thyroid function tests may misleadingly indicate euthyroidism, while the amount of T4 available for the fetus might be insufficient [24, 25]. Another commonly seen diagnostic marker of iodine deficiency is an elevated serum thyroglobulin level [26]. Serum Tg is well correlated with the severity of iodine deficiency as measured by UI [27]. Intervention studies examining the potential of Tg as an indicator of response to iodine supplementation revealed that Tg falls rapidly with iodine repletion and that Tg is a more sensitive indicator of iodine repletion than TSH or T4 [28, 29].

Iodine repletion in severely iodine-deficient pregnant women or infants may reduce the infant mortality rate by at least 50% [21]. A blinded, placebo-controlled clinical trial conducted in the 1960s in Papua, New Guinea, demonstrated that preconception supplementation of severely iodine-deficient women with iodinated oil eliminated the risk for cretinism and improved offspring cognitive function and survival [30]. These findings have subsequently been replicated in many regions of the world, indicating that iodine supplementation in severely iodine-deficient regions may increase the average child IQ by 12.5 points [31, 32].

Iodine supplementation of moderately deficient pregnant women appears to consistently decrease maternal and neonatal thyroid volumes and Tg levels [31]. Effects on maternal thyroid function have been variable, with significant maternal TSH decreases seen only in four of eight published studies and with increases in maternal T4 or FT4 noted in two studies [31]. The observed differences in the response to iodine supplementation may be related to the onset of intervention. In a prospective observational study, Moleti et al. studied 433 euthyroid anti-TPO antibody-negative women and observed TSH increases during gestation in 26.1% women taking 150 ug iodine supplementation during the pregnancy compared to 15.6% of women with a history of iodinated salt intake several months before the pregnancy (P < 0.05). However both methods of iodine supplementation were sufficient to reduce the proportion of pregnant women with hypothyroxinemia, which was observed in 8.3% of women taking 150 ug iodine supplements, 9.5% of women with a history of iodine salt use, and 20% of women without any iodine supplementation [33]. These observations were confirmed in other studies [34, 35]. Neurodevelopmental outcomes were improved in children whose mothers received iodine supplementation early in pregnancy and were lost if supplementation was started after the 10th week of pregnancy [36, 37].

These results suggest that women from mildly and moderately iodine-deficient areas, which include several European countries, should be advised to start iodine supplementation several months prior to conception in order to saturate intrathyroidal iodine stores. Ideally, women should have adequate intrathyroidal iodine stores (10–20 mg) before conception. Unfortunately, well-conducted randomized maternal iodine-supplementation studies with long-term follow-up data on psychomotor and mental development of children are lacking.

2.3. What are the Complications of Hypothyroidism/ Hypothyroxinemia and Autoimmune Thyroid Disease during the Pregnancy?

2.3.1. Hypothyroidism

**Pregnancy Complications.** There is a known association between hypothyroidism and decreased fertility, as well as increased risk for early and late obstetrical complications, such as increased prevalence of abortion, anemia, gestational hypertension, placental abruption, and postpartum hemorrhages. As would be expected, these complications are more
frequent with OH than with SH [38–43]. In one study of 216 women with early miscarriage, SH and AITD were independently associated with miscarriage with SH being specifically associated with very early embryo loss at 6.5 weeks [44]. In contrast, a prospective study of 10,990 women in US and Ireland with biochemical evidence of SH did not reveal excessive adverse pregnancy outcomes [45]. Recent studies from The Netherlands documented an association between TSH levels exceeding >2.4 mIU/mL between the 35th and 38th week of gestation are associated with the approximately 2-fold increased risk for breech presentation [46, 47]. Elevated TSH levels earlier during the pregnancy were not associated with risk of breech presentation. Interestingly, higher levels of TSH at end term were independently associated with the lack of successful outcome of external cephalic version [48].

Adverse Outcomes for the Neonate/Offspring. Untreated maternal OH is associated with adverse neonatal outcomes including premature birth, low birth weight, and neonatal respiratory distress. Although less frequent than with OH, complications have also been described in newborns from mothers with SH, including a doubling of the rate of preterm delivery [49] in pregnant women before 20 wk gestation. Stagnaro-Green et al. [50] compared the thyroid status of women with preterm delivery to matched controls who delivered at term and found a 3-fold increase in the incidence of SH in the women with very early preterm deliveries (before 32 wks).

Four decades ago Man et al. [51, 52] observed that children born to mothers with inadequately treated hypothyroidism had significantly reduced intelligence quotients (IQs). The first large-scale prospective study on the outcome of children born to mothers with SH during pregnancy was reported by Haddow et al. in 1999 [53]. In this study, extensive neuropsychological testing of the school-age children revealed that children born to women with untreated SH had on average an IQ score that was 7 points below the mean IQ of children born to healthy women and thyroxine-treated women. Furthermore, there were three times as many children with IQs that were 2 SD scores below the mean IQ of controls in the children born to untreated women with SH.

Of note, there is a specific type of combined maternal and fetal hypothyroidism during gestation associated with the presence of TSH receptor blocking antibodies in women with AITD. This entity is associated with more severe cognitive delay in the offspring than seen with either fetal or maternal hypothyroidism alone, probably because maternal T4 is unavailable to compensate for the fetal hypothyroidism. This disorder should be suspected if unusually high doses of levothyroxine (LT4) are required to normalize maternal thyroid function during gestation [54]. Additional studies will be required to elucidate the effect of SH on the long-term neuropsychological development of offspring.

2.3.2. Isolated Hypothyroxinemia

Pregnancy Complications. Cleary-Goldman et al. showed that isolated hypothyroxinemia, which was observed in 232 of 10,990 pregnant women, is not associated with adverse pregnancy outcomes [45]. Similar observations were noted by Casey et al. who observed hypothyroxinemia among 233 of 17,298 pregnant women. This was not associated with any increased risk for adverse pregnancy outcomes in this subpopulation [55].

Adverse Outcomes in Offspring. Despite the limitations of FT4 assays, multiple studies have demonstrated that low-normal FT4 concentrations are associated with adverse outcomes in the offspring. Pop et al. investigated the developmental outcome in children born to women with isolated low T4 levels in the first trimester of pregnancy, defined as values within the lowest 10th decile of “normal” pregnant T4 values [56]. Results suggested that isolated hypothyroxinemia is associated with a lower developmental index in the children at approximately 10 months of age. This observation was confirmed later by the same group based on a larger cohort and more refined motor and mental evaluations in infants aged 1 and 2 yrs [57]. They documented that children born to mothers with prolonged levels of low T4 (until wk 24 or later) showed an 8- to 10-point deficit for motor and mental development compared to infants of women whose serum FT4 levels recovered spontaneously to normal later in gestation.

These results were confirmed by Vermiglio et al. [22], who compared the neuropsychological development of children of mothers from a moderately iodine-deficient area to that of children of mothers from a marginally iodine-sufficient area. The offspring of the mothers with lower FT4 values during gestation were found to have an increased incidence of attention deficit and hyperactivity disorder as well as a reduced IQ, compared with controls. Similarly, Kooistra et al. observed that newborns from hypothyroxinemic mothers (FT4 below the 10th percentile at 12th week of pregnancy), and evaluated 3 weeks after delivery with the Neonatal Behavioural Assessment Scale, had significantly lower orientation index scores compared to children whose mothers had FT4 levels between the 50th and 90th percentiles [58]. Similar observation was found in Chinese population, indicating that children of women with either SH, hypothyroxinemia, or elevated TPO Ab titres at 16–20 weeks gestation had mean intelligence and motor scores significantly lower than controls [59]. Finally, a recent population-based cohort study from The Netherlands involving 3659 children and their mothers documented that both mild (below the 10th percentile) and severe (below 5 percentile) maternal hypothyroxinemas were associated with a higher risk of expressive language delay at 18 and 30 months. Severe maternal hypothyroxinemia also predicted a higher risk of nonverbal cognitive delay [60].

2.3.3. Euthyroid Autoimmune Thyroid Disease

Pregnancy Complications. Experimental studies on pregnant mice have shown an increased rate of miscarriage after immunization with Tg [61, 62]. Several studies have also indicated an association in women between the presence of AITD and an increased miscarriage rate and preterm
delivery [63–65]. Three hypotheses have been proposed to explain this association: (1) thyroid antibodies may represent a marker of a generalized autoimmune imbalance that increases risk of miscarriage; (2) preexisting subtle thyroid dysfunction due toAITD may worsen during pregnancy; (3) because women withAITD have a higher prevalence of infertility, they may be older than those withoutAITD and thus be more prone to fetal loss. Women withAITD are also more likely to suffer from postpartum thyroiditis and postpartum depression [66–69].

Side Effects in the Offspring. As far as we could determine, other than the one study cited above [59], there is no other evidence that high maternal TPOAb titers are associated with a delayed neurologic development of the offspring.

2.3.4. Euthyroid TPO Ab Negative Women with TSH between 2.5 and 5 mIU/L

Pregnancy Complications. A higher rate of spontaneous pregnancy loss was observed in a study of 642 women with serum TSH ranging between 2.5 and 5 mIU/L in the first trimester than in 3481 women with TSH below 2.5 (6.1% versus 3.6%, \( P = 0.006 \), resp.) [70].

2.4. Is Levothyroxine Therapy Beneficial and Effective in regard to Improved Outcomes and Reduced Complications Associated with Pregnancy and Delivery?

Based upon data in the study by Abalovich et al. [38] focused on 150 pregnancy outcomes in 114 women who had either OH (\( n = 52 \)) or SH (\( n = 62 \)) (Table 1), Stagnaro-Green analyzed the preterm delivery rate of women who were either adequately treated at conception (\( n = 99 \)) or during pregnancy (\( n = 27 \)) versus women who were inadequately treated during pregnancy (\( n = 24 \)). The analysis revealed a significantly lower preterm delivery rate of 1.6% after adequate treatment with LT4 compared to a rate of 12.5% in the group of inadequately treated women with TSH > 4 mIU/L during pregnancy (\( P < 0.05 \)) [74]. There is also evidence that LT4 treatment can improve implantation rate and live birth rate in infertile women with subclinical hypothyroidism undergoing in vitro fertilization [75].

Rovet [76] investigated children up to the age of 5 born to women who, although having been treated for hypothyroidism during pregnancy, received suboptimal LT4 dosage as indicated by mean TSH levels between 5 and 7 mIU/liter. The children at preschool age were found to have a mild reduction in global intelligence that was inversely correlated with maternal TSH level during the third trimester. No negative impact was noted on language, visual spatial ability, fine motor performance, or preschool ability.

Preliminary results of the “Controlled Antenatal Thyroid Screening Study” (CATS) were presented in September 2010 during International Thyroid Congress [73]. The CATS trial was a prospective randomized study that screened 22,000 women within the 16th week of gestation for thyroid status with TSH and FT4 measurements. Women with FT4 values lower than the 2.5th percentile and/or TSH values above the 97.5th percentile were randomly assigned into an intervention group treated with LT4 or a control group without intervention. Neuropsychological development assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPS III) was performed in the offspring of both groups at 3 years of age. Primary outcomes consisted of the mean WPPS III score and the percentage of offspring with IQ of <85 points. A primary analysis that included an intention to treat analysis revealed no significant differences. The secondary analysis which excluded women who had been noncompliant with LT4 treatment also revealed no difference in relative risk of full-scale IQ being below 85 in the screened group compared to the control group.

A second study is presently in progress under the auspices of the NIH. Pregnancy screening was initiated in October 2006, and study completion is anticipated in 2015. That study will eventually comprise a total of 120,000 pregnant women, recruited from an obstetrical US network of 14 institutions. Women with SH or isolated hypothyroxinemia will be randomized to placebo versus LT4 treatment to normalize serum TSH in women with SH or to normalize serum FT4 in women with isolated hypothyroxinemia [77]. The primary outcome of the study will be intellectual function of children at 5 years of age as measured by the WPPSI-III. The WPPSI-III scores of progeny of treated women will be compared to the children of untreated women. Secondary outcomes of the study include assessment of fetal growth, rates of preterm delivery, preeclampsia, placental abruption, stillbirth, and development of postpartum thyroid dysfunction.

2.4.1. Euthyroid Women withAITD. Negro et al. published the first study focused on the possible benefit of LT4 treatment of anti-TPO positive euthyroid women defined as having serum TSH within a range 0.27–4.2 mIU/L [72]. Among 984 patients who completed the study, there were 155 anti-TPO positive women randomized into an intervention group (\( n = 57 \)) treated with LT4 at their first prenatal visit performed at a median 10 weeks of gestation and a no intervention group (\( n = 58 \)). TPO Ab negative women (\( n = 869 \)) served as a normal control group. This study importantly demonstrated salutary effects of LT4 administration to both correct maternal thyroid dysfunction and also decrease the rate of adverse obstetrical events such as miscarriage and premature delivery, bringing their prevalence down to those of the control population (Table 1). No study has yet demonstrated whether similar benefit might be gained with LT4 therapy of TPO Ab negative women.

2.5. How to Select the Patients for Whom the Treatment May Be Beneficial?

2.5.1. Screening for Thyroid Dysfunction during Pregnancy. In view of the growing evidence that abnormal thyroid function during pregnancy is associated with less optimal outcomes that can be improved with LT4 treatment, the question arises as to whether to screen in early pregnancy for thyroid dysfunction. The 2007 Endocrine Society Guidelines
Table 1: Intervention studies describing the efficacy of L T4 treatment during pregnancy.

| Study               | Design              | Material                                                                 | Intervention                                                                 | Target TSH                                      | Pregnancy complications | Offspring complications |
|---------------------|---------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------|------------------------|------------------------|
| Abalovich et al. [38] | Retrospective study of pregnant women with OH TSH > 5 mIU/L, T4 < 4.5 ug/dL and SH TSH > 5 mIU/L, T4 normal | 114 women OH n = 52 SH n = 52 99 pregnancies conceived under euthyroidism, 51 under OH or SH | Treatment with L T4 before or during pregnancy as soon as OH or SH was diagnosed | Optimal treatment TSH < 4 mIU/mL  Inadequate treatment TSH > 4 mIU/mL | Among pregnancies conceived under OH or SH miscarriage rate inadequate versus adequate treated 60% versus 0% in OH and 71.4% versus 0% in SH | Among pregnancies conceived under OH or SH preterm deliveries rate inadequate versus adequate treated 20% versus 0% in OH and 7.2% versus 9.5% in SH |
| Hallengren et al. [71] | Prospective observational study | 63 pregnant women with OH treated with LT4 | Adjustment of the LT4 dose <2 mIU/L | Fetal loss 6% (2/32) of optimally treated patients versus 29% (9/31) of women treated inadequately | Not examined |
| Negro et al. [72] | Prospective randomized trial | 984 euthyroid women with TSH levels <4.2 mIU/L | Dose of LT4 stable during pregnancy 0.5 ug/kg/d for TSH < 1.0 mIU/L 0.75 ug/kg/d TSH 1.0-2.0 mIU/L, 1 ug/kg/d TSH > 2.0 mIU/L or anti-TPO > 1500 kIU/L | The rate of miscarriage lower in intervention group A compared to group B (3.5% versus 13.8%, P < 0.05) and similar to controls (3.5% versus 2.4%, P = ns) | Not examined |
| CATS study Lazarus [73] | Prospective randomized trial | 22,000 women within the 16th week of gestation | In the intervention group L T4 was initiated during pregnancy in women with FT4 values lower than the 2.5th percentile and/or TSH values above the 97.5th percentile. The control group received no intervention. | No data | The primary outcome was the mean WPPS-III score and the percentage of offspring with IQ < 85 points. The primary intention to treat analysis revealed no significant differences. A secondary analysis excluded women noncompliant with LT4 and also revealed no difference in relative risk of full scale IQ being below 85 in the screen group compared to the control group. |

[6] recommend case finding by measurement of TSH in women in any of the following categories:

(1) personal history of abnormal thyroid function,
(2) family history of thyroid disease,
(3) goiter,
(4) positive thyroid antibodies,
(5) symptoms or clinical signs suggestive of thyroid dysfunction,
(6) type 1 diabetes,
(7) other autoimmune disorders,
(8) infertility,
(9) history of therapeutic head or neck irradiation,
(10) history of miscarriage or preterm delivery.

However, it has been suggested that we might fail to detect 30% of hypothyroid and 69% of hyperthyroid women if only high-risk pregnant women are screened [78]. This argument is supported by demonstrating that screening a low-risk group identified both hypothyroidism and hyperthyroidism and allowed early therapy that resulted in a lower rate of adverse obstetrical and fetal outcomes [79]. While a major argument against screening is the associated cost of TSH measurements, it has been demonstrated that screening pregnant women with TSH in the first trimester of pregnancy is cost-saving compared with no screening and screening by measurement of anti-TPO antibodies is also an economically favorable screening strategy [80].

2.6. What is the Appropriate Treatment Regimen; What are Target Thyroid Function Test Values, and How Often Should They Be Monitored?

Once a diagnosis of either OH or SH is made during pregnancy, the Guidelines of the Endocrine Society clearly recommend initiation of treatment with LT4 [6].

“LT4 dose often needs to be incremented by 4–6 wk gestation and may require a 30–50% increment in dosage. If overt hypothyroidism is diagnosed during pregnancy, thyroid function tests should be normalized as rapidly as possible. The target threshold TSH should be less than 2.5 mIU/L in the first trimester and less than 3 mIU/L in second and third trimesters or to trimester-specific normal TSH ranges. Thyroid function tests should be remeasured within 30–40 d. After delivery, most hypothyroid women need to decrease the thyroxine dosage they received during pregnancy.” [6]

Notwithstanding the data extant demonstrating efficacy of LT4 therapy in preventing adverse pregnancy and offspring outcomes and the availability of published guidelines addressing the treatment strategy, there is evidence that 24–49% of women treated with LT4 before conception still have elevated TSH levels at their first prenatal visit [71, 81, 82]. The reasons for this are not clear but could include failure to appreciate and recognize that dosage requirements for LT4 may change with pregnancy as well as perhaps failure to reevaluate TSH at sufficiently frequent intervals. In women already taking LT4, the magnitude of increase in LT4 requirements with pregnancy is approximately 40–50% of the preconception dosage in athyreotic patients and about 20–30% for patients with underlying Hashimoto’s thyroiditis [6, 83–89]. The difference is due to the fact that the latter patients typically will have some residual functioning mass of thyroid tissue capable of releasing T4 that complements the daily exogenous LT4 dose.

Because of the potential for clinicians to fail to identify the demand for an increased LT4 dosage in pregnancy, several studies have aimed to identify a practical therapeutic approach to address this issue [90]. Rotondi et al. [91] pointed out that the intervention should be made preconception. They prospectively examined 25 women with compensated hypothyroidism of different etiology anticipating pregnancy and assigned them to two groups: 14 patients had their LT4 dose increased to a partially suppressive dose, while 11 patients continued the same therapeutic regimen. Their results indicated that a preconception dosage of LT4 targeted at TSH in the lower quartile of the reference range may result in adequate maternal thyroid function up to the first postconception evaluation. This observation is in agreement with a retrospective study by Abalovich et al. of 53 women with compensated hypothyroidism defined as a TSH <2.5 mIU/L six months prior to conception. When the preconception TSH was below 1.2 mIU/mL, only 17.2% of women required incremental LT4 adjustment during the pregnancy compared to 50% of women having a preconception TSH between 1.2 and 2.4 mIU/mL (P < 0.02) [92].

These data support the logic of the premise that women will need varying degrees of adjustment of their prepregnancy LT4 dosage based upon the underlying cause of their thyroid dysfunction. The best example of this was demonstrated by Loh et al. [93] who observed that patients with a history of thyroid cancer on doses of LT4 sufficient to suppress preconception TSH required smaller and less frequent incremental adjustments of LT4 during the pregnancy in order to keep TSH within the normal range than did patients suffering from other causes of hypothyroidism. Some investigators have proposed a simple and practical formula to address this issue, suggesting that hypothyroid women on LT4 should be advised that once pregnant they should increase their LT4 dose by about 25% by taking two extra doses per week of their usual daily dose of LT4 [94]. Other than the consideration of the cost of additional TSH measurements throughout pregnancy, we would propose that assurance of euthyroidism during pregnancy is best obtained by an individualized approach to LT4 dosage adjustment based on a TSH measurement done every 2 weeks during the first trimester and then less frequently thereafter as suggested by Burman [95].

The very recent THERAPY trial (Thyroid Hormone Early Adjustment in Pregnancy) proposed another approach [96]. Sixty women with treated hypothyroidism were prospectively randomized before their anticipated pregnancy to one of two groups who received an increased LT4 dose of either 2 or 3 tablets per week once pregnancy was confirmed. Enrollment took place at a median 5.5 weeks of pregnancy, and patients were followed with the measurements of TSH, TT4, and thyroid hormone binding ratio every 2 weeks through week 20 and then once again at 30 weeks. Interestingly, despite the early enrollment, nearly 30% of women were already hypothyroid. The authors documented that increasing LT4 by 2 tablets per week resulted in the achievement of TSH below 2.5 mIU/L during the first trimester in 85% of patients without a significantly increased risk of iatrogenic hyperthyroidism, which was observed in 2/25 patients compared with
the group receiving a 3-tablet per week increment, in which suppressed TSH was observed in 14/23 women. This study also assessed the optimal follow-up strategy throughout the remainder of pregnancy; documenting that 92% of abnormal TSH values would be detected by testing every 4 weeks.

Based upon this review of the literature, it appears clear that there is a necessity to both update and promulgate novel guidelines in regard to LT4 treatment during pregnancy. In addition to the endocrine community, the guidelines importantly should reach a target population of obstetricians and family care physicians who provide the majority of antenatal care. Indeed, according to one study of obstetricians and general practitioners in Wisconsin, there is currently a limited awareness of the 2007 Endocrine Society Guidelines in only 11.5% of the latter population of caregivers [97].

2.6.1. A Future Research Agenda That Could Illuminate Remaining Aspects of the Care of Pregnant Women with Thyroid Dysfunction Might Include the Following.

(1) Determination of which strategy is most appropriate, universal screening, or case finding, based on large prospective trials like CATS and NIHS trial.

(2) Assessment of the best screening strategy (TSH versus anti-TPO Ab versus TSH + anti-TPO Ab) in different populations characterized by various iodine nutritional status.

(3) Examining the effects of LT4 treatment of SH and isolated hypothyroxinemia on the long-term intellectual development of offspring.

(4) A study of the efficacy of LT4 treatment of TPO Ab negative women with preconception TSH levels >2.5 mIU/L.

(5) Confirmation of whether the optimal preconception target TSH concentration is 1.2 mIU/L versus 1.2–2.5 mIU/L.

3. Addendum

After the acceptance of this review for the publication, the new Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum were released online [98].

The content of this review is concordant with ATA guidelines in the following recommendations.

(1) Trimester and population specific reference ranges for TSH should be applied. If they are not available in the laboratory, the following reference ranges are recommended: first trimester, 0.1–2.5 mIU/L; second trimester, 0.2–3.0 mIU/L; third trimester, 0.3–3.0 mIU/L.

(2) Method-specific and trimester-specific reference ranges of serum FT4 are required.

(3) All women with hypothyroidism and women with subclinical hypothyroidism who are positive for TPOAb should be treated with LT4; however due to the lack of randomized controlled trials there is insufficient evidence to recommend for or against universal LT4 treatment in TPO Ab negative pregnant women with subclinical hypothyroidism.

(4) The goal of LT4 treatment is to normalize maternal serum TSH values within the trimester-specific pregnancy reference range.

(5) LT4 dose should be increased by 25–30% upon a missed menstrual cycle or positive home pregnancy test. This adjustment can be accomplished by increasing LT4 by additional 2 tablets of LT4 per week. Further adjustments should be individualized as they are dependent on the etiology of maternal hypothyroidism, as well as the preconception level of TSH. Serum thyroid function tests should be monitored closely.

(6) Hypothyroid patients (receiving LT4) who are planning pregnancy should have their dose adjusted by their provider in order to optimize serum TSH values to <2.5 mIU/L preconception.

Some controversial problems pointed out in this review have been addressed by the guidelines in the following manner.

(1) Euthyroid women (not receiving LT4) who are TPOAb positive require monitoring for hypothyroidism during pregnancy.

(2) Serum TSH should be evaluated every 4 weeks during the first half of pregnancy and at least once between 26 and 32 weeks gestation.

(3) Isolated hypothyroxinemia should not be treated in pregnancy, because of the lack of a documented effect of this intervention.

Some controversial problems included in this review that remain unsolved or not addressed.

(1) There is insufficient evidence to recommend for or against screening for TPO Ab in the first trimester of pregnancy, or treating TPO Ab positive euthyroid women with LT4.

(2) There is insufficient evidence to recommend for or against universal TSH screening at the first trimester visit.

References

[1] D. Glinoer, “The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology,” Endocrine Reviews, vol. 18, no. 3, pp. 404–433, 1997.

[2] G. E. Krassas, K. Poppe, and D. Glinoer, “Thyroid function and human reproductive health,” Endocrine Reviews, vol. 31, no. 5, pp. 702–735, 2010.

[3] D. Glinoer, “The regulation of thyroid function during normal pregnancy: importance of the iodine nutrition status,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 18, no. 2, pp. 133–152, 2004.
[4] R. C. Smallridge, D. Glinocer, J. G. Hollowell, and G. Brent, “Thyroid function inside and outside of pregnancy: what do we know and what don’t we know?” *Thyroid*, vol. 15, no. 1, pp. 54–59, 2005.

[5] W. C. Allan, J. E. Haddow, G. E. Palomaki et al., “Maternal thyroid deficiency and pregnancy complications: implications for population screening,” *Journal of Medical Screening*, vol. 7, no. 3, pp. 127–130, 2000.

[6] M. Abalovich, N. Amino, L. A. Barbour et al., “Clinical practice guideline: management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline,” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 8, pp. S1–S47, 2007.

[7] R. Z. Klein, J. E. Haddow, J. D. Faix et al., “Prevalence of thyroid deficiency in pregnant women,” *Clinical Endocrinology*, vol. 35, no. 1, pp. 41–46, 1991.

[8] S. M. Reid, P. Middleton, M. C. Cossich, and C. A. Crowther, “Interventions for clinical and subclinical hypothyroidism in pregnancy,” *Cochrane Database of Systematic Reviews*, vol. 7, Article ID CD007752, pp. 1–34, 2010.

[9] A. McElduff and J. Morris, “Thyroid function tests and thyroid autoantibodies in an unselected population of women undergoing first trimester screening for aneuploidy,” *Australian and New Zealand Journal of Obstetrics and Gynaecology*, vol. 48, no. 5, pp. 478–480, 2008.

[10] WHO, *Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination*, WHO Press, Geneva, Switzerland, 3rd edition, 2007.

[11] T. Männistö, H. M. Surcel, A. Ruokonen et al., “Early pregnancy reference intervals of thyroid hormone concentrations in a thyroid antibody-negative pregnant population,” *Thyroid*, vol. 21, no. 3, pp. 291–298, 2011.

[12] B. M. Shields, R. M. Freathy, B. A. Knight et al., “Phosphodiesterase 8B gene polymorphism is associated with subclinical hypothyroidism in pregnancy,” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 11, pp. 4608–4612, 2009.

[13] N. S. Panesar, C. Y. Li, and M. S. Rogers, “Reference intervals for thyroid hormones in pregnant Chinese women,” *Annals of Clinical Biochemistry*, vol. 38, no. 4, pp. 329–332, 2001.

[14] R. M. Gilbert, N. C. Haddow, J. P. Walsh et al., “Assessment of thyroid function during pregnancy: first-trimester (weeks 9–13) reference intervals derived from Western Australian women,” *Medical Journal of Australia*, vol. 189, no. 5, pp. 250–253, 2008.

[15] E. N. Pearce, E. Oken, M. W. Gillman et al., “Association of first-trimester thyroid function test values with thyroidoxidase antibody status, smoking, and multivitamin use,” *Endocrine Practice*, vol. 14, no. 1, pp. 33–39, 2008.

[16] R. Stricker, M. Echenard, R. Eberhart et al., “Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals,” *European Journal of Endocrinology*, vol. 157, no. 4, pp. 509–514, 2007.

[17] M. d’Herbomez, G. Forzy, F. Gasser, C. Massart, A. Beaudonnet, and R. Sapin, “Clinical evaluation of nine free thyroxine assays: persistent problems in particular populations,” *Clinical Chemistry and Laboratory Medicine*, vol. 41, no. 7, pp. 942–947, 2003.

[18] R. Sapin and M. D’Herbomez, “Free thyroxine measured by equilibrium dialysis and nine immunoasays in sera with various serum thyroxine-binding capacities,” *Clinical Chemistry*, vol. 49, no. 9, pp. 1531–1535, 2003.

[19] R. H. Lee, C. A. Spencer, J. H. Mestman et al., “Free T4 immunoasays are flawed during pregnancy,” *American Journal of Obstetrics and Gynecology*, vol. 200, no. 3, pp. 260.e1–260.e6, 2009.

[20] L. M. Demers, C. A. Spencer, T. F. Davies et al., “Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease,” *Thyroid*, vol. 13, no. 1, pp. 3–126, 2003.

[21] M. B. Zimmermann, “Iodine deficiency,” *Endocrine Reviews*, vol. 30, no. 4, pp. 376–408, 2009.

[22] F. Vermiglio, V. P. Lo Presti, M. Moleti et al., “Attention deficit and hyperactivity disorders in the offspring of mothers exposed to mild-moderate iodine deficiency: a possible novel iodine deficiency disorder in developed countries,” *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 12, pp. 6054–6060, 2004.

[23] B. de Benoist, M. Andersson, B. Takkouche, and J. Egli, “Prevalence of iodine deficiency worldwide,” *Lancet*, vol. 362, no. 9398, pp. 1859–1860, 2003.

[24] G. Morreale De Escobar, M. J. Ohregren, and F. Escobar Del Rey, “Clinical perspective: is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia?” *Journal of Clinical Endocrinology and Metabolism*, vol. 85, no. 11, pp. 3975–3987, 2000.

[25] A. Melse-Boonstra and N. Iaiswal, “Iodine deficiency in pregnancy, infancy and childhood and its consequences for brain development,” *Best Practice and Research: Clinical Endocrinology and Metabolism*, vol. 24, no. 1, pp. 29–38, 2010.

[26] A. I. Van Herle, J. M. Hershman, R. W. Hornbrook, and I. J. Chopra, “Serum thyroglobulin in inhabitants of an endemic goiter region of New Guinea,” *Journal of Clinical Endocrinology and Metabolism*, vol. 43, no. 3, pp. 512–516, 1976.

[27] N. Knudsen, I. Bülow, T. Jørgensen, H. Perrild, L. Ovesen, and P. Laurberg, “Serum Tg - A sensitive marker of thyroid abnormalities and iodine deficiency in epidemiological studies,” *Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 8, pp. 3599–3603, 2001.

[28] M. Benmiloud, M. L. Chaouki, R. Gutekunst, H. M. Teichert, W. G. Wood, and J. T. Dunn, “Oral iodized oil for correcting iodine deficiency: optimal dosing and outcome indicator selection,” *Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 1, pp. 20–24, 1994.

[29] U. Missler, R. Gutekunst, and W. G. Wood, “Thyroglobulin is a more sensitive indicator of iodine deficiency than thyrotropin: development and evaluation of dry blood spot assays for thyrotropin and thyroglobulin in iodine-deficient geographical areas,” *European Journal of Clinical Chemistry and Clinical Biochemistry*, vol. 32, no. 3, pp. 137–143, 1994.

[30] P. O. D. Pharoah and K. J. Connolly, “A controlled trial of iodinated oil for the prevention of endemic cretinism: a long-term follow-up,” *International Journal of Epidemiology*, vol. 16, no. 1, pp. 68–73, 1987.

[31] E. N. Pearce, “What do we know about iodine supplementation in pregnancy?” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 9, pp. 3188–3190, 2009.

[32] M. Qian, D. Wang, W. E. Watkins et al., “The effects of iodine on intelligence in children: a meta-analysis of studies conducted in China,” *Asia Pacific Journal of Clinical Nutrition*, vol. 14, no. 1, pp. 32–42, 2005.

[33] M. Moleti, B. Di Bella, G. Giorgianni et al., “Maternal thyroid function in different conditions of iodine nutrition in pregnant women exposed to mild-moderate iodine deficiency: an observational study,” *Clinical Endocrinology*, vol. 74, no. 6, pp. 762–768, 2011.
[34] M. Moleti, V. P. L. Presti, M. C. Campolo et al., “Iodine prophylaxis using iodized salt and risk of maternal thyroid failure in conditions of mild iodine deficiency,” *Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 7, pp. 2616–2621, 2008.

[35] M. Rebagliato, M. Murcia, M. Espada et al., “Iodine intake and maternal thyroid function during pregnancy,” *Epidemiology*, vol. 21, no. 1, pp. 62–69, 2010.

[36] I. Velasco, M. Carreira, P. Santiago et al., “Ectopic C-reactive protein and thyroid autoimmunity,” *Human Reproduction*, vol. 26, no. 1, pp. 10, 2011.

[37] L. Kooistra, S. Crawford, A. L. van Baar, and V. J. Pop, “Neonatal effects of maternal hypothyroxinemia during early pregnancy,” *Clinical Endocrinology*, vol. 72, no. 6, pp. 825–829, 2010.

[38] J. H. Mestman, “Hypothyroidism complicating pregnancy,” *Obstetrics and Gynecology*, vol. 72, no. 6, pp. 825–829, 2010.

[39] M. Imaizumi, A. Pritsker, M. Kita, L. Ahmad, P. Unger, and T. F. Davies, “Pregnancy and murine thyroiditis: thyroglobulin immunization leads to fetal loss in specific allogeneic pregnancies,” *Clinical Endocrinology*, vol. 16, no. 8, pp. 549–555, 1999.

[40] Y. Li, Z. Shan, W. Teng et al., “Abnormalities of maternal thyroid function during pregnancy: implications for population screening,” *Journal of Medical Screening*, vol. 7, no. 3, pp. 127–130, 2000.

[41] L. E. Davis, K. J. Leveno, and F. G. Cunningham, “Hypothyroidism complicating pregnancy,” *Obstetrics and Gynecology*, vol. 72, no. 2, pp. 108–112, 1988.

[42] J. Pop, “Neonatal effects of maternal hypothyroxinemia during early pregnancy,” *Clinical Endocrinology*, vol. 95, no. 9, pp. 1227–1231, 2007.

[43] A. S. Leung, K. M. Millar, P. Koonings, M. Montoro, and J. H. Mestman, “Perinatal outcome in hypothyroid pregnancies,” *Obstetrics and Gynecology*, vol. 81, no. 3, pp. 349–353, 1993.

[44] M. Montoro, J. V. Collea, S. D. Frasier, and J. H. Mestman, “Successful outcome of pregnancy in women with hypothyroidism,” *Annals of Internal Medicine*, vol. 94, no. 1, pp. 31–34, 1981.

[45] G. Ashoor, N. Maiz, M. Rotas, L. Jawdat, and K. H. Nicoldes, “Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death,” *Thyroid*, vol. 20, no. 9, pp. 989–993, 2010.

[46] A. De Vivo, A. Mancuso, A. Giacobbe et al., “Thyroid function in women found to have early pregnancy loss,” *Thyroid*, vol. 20, no. 6, pp. 633–637, 2010.

[47] J. Cleary-Goldman, F. D. Malone, G. Lambert-Messerlian et al., “Maternal thyroid hypofunction and pregnancy outcome,” *Obstetrics and Gynecology*, vol. 112, no. 1, pp. 85–92, 2008.

[48] L. Kooistra, S. M. Kuppens, T. H. Hasaart et al., “High thyrotrophin levels at end term increase the risk of breech presentation,” *Clinical Endocrinology*, vol. 73, no. 5, pp. 661–665, 2010.

[49] S. M. I. Kuppens, L. Kooistra, H. A. Wijnen et al., “Maternal thyroid function during gestation is related to breech presentation at term,” *Clinical Endocrinology*, vol. 72, no. 6, pp. 820–824, 2010.

[50] A. Stagnaro-Green, X. Chen, J. D. Bogden, T. F. Davies, and T. O. Scholl, “The thyroid and pregnancy: a novel risk factor for very preterm delivery,” *Thyroid*, vol. 15, no. 4, pp. 351–357, 2005.

[51] E. B. Man, W. S. Jones, R. H. Holden, and E. David Mellits, “Thyroid function in human pregnancy. Retardation of pregnancy aged 7 years; relationships to maternal age and maternal thyroid function,” *American Journal of Obstetrics and Gynecology*, vol. 111, no. 7, pp. 905–916, 1971.

[52] E. B. Man, J. F. Cunningham, and S. A. Serunian, “Maternal hypothyroxinemia: psychoneurological deficits of progeny,” *Annals of Clinical and Laboratory Science*, vol. 21, no. 4, pp. 227–239, 1991.

[53] J. E. Haddow, G. E. Palomaki, W. C. Allan et al., “Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child,” *New England Journal of Medicine*, vol. 341, no. 8, pp. 549–555, 1999.

[54] R. S. Brown, G. Van Vliet, and S. Downing, “Developmental outcome of babies with TSH receptor blocking antibody-induced congenital hypothyroidism,” *Pediatric Research*, vol. 49, p. 157, 2001, abstract P1-937.

[55] B. M. Casey, J. S. Dashe, C. Y. Spong, D. D. McIntire, K. J. Leveno, and G. F. Cunningham, “Perinatal significance of isolated maternal hypothyroxinaemia identified in the first half of pregnancy,” *Obstetrics and Gynecology*, vol. 109, no. 5, pp. 1129–1135, 2007.

[56] V. J. Pop, J. L. Kuijpers, A. L. van Baar et al., “Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy,” *Clinical Endocrinology*, vol. 50, no. 2, pp. 147–155, 1999.

[57] T. F. Davies, “Pregnancy and murine thyroiditis: thyroglobulin immunization leads to fetal loss in specific allogeneic pregnancies,” *Clinical Endocrinology*, vol. 72, no. 6, pp. 825–829, 2010.

[58] J. Henrichs, J. J. Bongers-Schokking, J. J. Schenk et al., “Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 9, pp. 4227–4234, 2010.

[59] S. T. Matalon, M. Blank, Y. Levy et al., “The pathogenic role of anti-thyroglobulin antibody on pregnancy: evidence from an active immunization model in mice,” *Human Reproduction*, vol. 18, no. 5, pp. 1094–1099, 2003.

[60] M. Imai, M. Kita, L. Ahmad, P. Unger, and T. F. Davies, “Pregnancy and murine thyroiditis: thyroglobulin immunization leads to fetal loss in specific allogeneic pregnancies,” *Endocrinology*, vol. 142, no. 2, pp. 823–829, 2001.

[61] D. Cilino, M. Riahi, J. P. Grun, and J. Kinthaert, “Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders,” *Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 1, pp. 197–204, 1994.

[62] F. Ghafoor, M. Mansoor, T. Malik et al., “Role of thyroid peroxidase antibodies in the outcome of pregnancy,” *Journal of the College of Physicians and Surgeons Pakistan*, vol. 16, no. 7, pp. 468–471, 2006.
A. Stagnaro-Green and D. Glinoer, “Thyroid autoimmunity and the risk of miscarriage,” *Best Practice and Research: Clinical Endocrinology and Metabolism*, vol. 18, no. 2, pp. 167–181, 2004.

V. J. Pop, H. A. de Rooy, H. L. Vader, D. Van Der Heide, M. M. Van Son, and I. H. Komproe, “Microsomal antibodies during gestation in relation to postpartum thyroid dysfunction and depression,” *Acta Endocrinologica*, vol. 129, no. 1, pp. 26–30, 1993.

B. Harris, S. Othman, J. A. Davies et al., “Association between postpartum thyroid dysfunction and thyroid antibodies and depression,” *British Medical Journal*, vol. 305, no. 6846, pp. 152–156, 1992.

J. L. Kuipens, H. L. Vader, H. A. Drexhage, W. M. Wiersinga, M. J. Van Son, and V. J. Pop, “Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum,” *European Journal of Endocrinology*, vol. 145, no. 5, pp. 579–584, 2001.

A. Caixàs, M. Albareda, A. García-Patterson, J. Rodríguez-Espinosa, A. De Leiva, and R. Corcoy, “Postpartum thyroiditis in women with hypothyroidism antedating pregnancy?” *Journal of Clinical Endocrinology and Metabolism*, vol. 84, no. 11, pp. 4000–4005, 1999.

R. Negro, A. Schwartz, R. Gismondi, A. Tinelli, T. Mangieri, and A. Stagnaro-Green, “Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 9, pp. 44–48, 2010.

B. Hallengren, M. Lantz, B. Andreasson, and L. Grennert, “Pregnant women on thyroxine substitution are often dysregulated in early pregnancy,” *Thyroid*, vol. 19, no. 4, pp. 391–394, 2009.

R. Negro, G. Formoso, T. Mangieri, A. Pezzarossa, D. Dazzi, and H. Hassan, “Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications,” *Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 7, pp. 2587–2591, 2006.

J. Lazarus, “Outcome of the CATS study,” in *Proceedings of the 18th Symposium of ITC Meeting*, Paris, France, September 2010.

A. Stagnaro-Green, “Maternal thyroid disease and preterm delivery,” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 1, pp. 21–25, 2009.

C. -H. Kim, J. -W. Ahn, S. P. Kang, S. -H. Kim, H. -D. Chae, and B. -M. Kang, “Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection,” *Fertility and Sterility*, vol. 95, no. 5, pp. 1650–1654, 2011.

J. F. Rovet, “Neurodevelopmental consequences of maternal hypothyroidism during pregnancy,” *Thyroid*, vol. 14, p. 710, 2004, abstract 88; annual meeting of the American Thyroid Association.

B. M. Casey and C. Y. Spong, “A randomized trial of thyroxine therapy for subclinical hypothyroidism or hypothyroxinemia diagnosed during pregnancy. Thyroid dysfunction and pregnancy: miscarriage, preterm delivery and decreased IQ,” in *Booklet of the Research Summit and Spring Symposium of the American Thyroid Association*, American Thyroid Association, Washington, DC, USA, 2009.

B. Vaidya, S. Anthony, M. Bilous et al., “Brief report: detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding?” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 1, pp. 203–207, 2007.

R. Negro, A. Schwartz, R. Gismondi, A. Tinelli, T. Mangieri, and A. Stagnaro-Green, “Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 4, pp. 1699–1707, 2010.

C. Dosios, G. D. Sanders, S. S. Araki, and L. M. Crapo, “Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis,” *European Journal of Endocrinology*, vol. 158, no. 6, pp. 841–851, 2008.

I. Idris, R. Srinivasan, A. Simm, and R. C. Page, “Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome,” *Clinical Endocrinology*, vol. 63, no. 5, pp. 560–565, 2005.

M. R. McClain, G. Lambert-Messerlian, J. E. Haddow et al., “Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study,” *American Journal of Obstetrics and Gynecology*, vol. 199, no. 2, pp. 129.e1–129.e6, 2008.

F. Pekonen, K. Teramo, E. Ikonen et al., “Women on thyroid hormone therapy: pregnancy course, fetal outcome, and amniotic fluid thyroid hormone level,” *Obstetrics and Gynecology*, vol. 63, no. 5, pp. 635–638, 1984.

S. J. Mandel, P. R. Larsen, E. W. Seely, and G. A. Brent, “Increased need for thyroxine during pregnancy in women with primary hypothyroidism,” *New England Journal of Medicine*, vol. 323, no. 2, pp. 91–96, 1990.

H. Tamaki, N. Amino, K. Takeoka, N. Mitsuda, K. Miyai, and O. Tanizawa, “Thyroxine requirement during pregnancy for replacement therapy of hypothyroidism,” *Obstetrics and Gynecology*, vol. 76, no. 2, pp. 230–233, 1990.

M. M. Kaplan, “Monitoring thyroxine treatment during pregnancy,” *Thyroid*, vol. 2, no. 2, pp. 147–152, 1992.

J. C. Girling and M. de Swiet, “Thyroxine dosage during pregnancy in women with primary hypothyroidism,” *British Journal of Obstetrics and Gynaecology*, vol. 99, no. 5, pp. 368–370, 1992.

I. R. McDougall and N. Maclin, “Hypothyroid women need more thyroxine when pregnant,” *Journal of Family Practice*, vol. 41, no. 3, pp. 238–240, 1995.

I. J. Chopra and K. Baber, “Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy?” *Metabolism*, vol. 52, no. 1, pp. 122–128, 2003.

S. J. Mandel, C. A. Spencer, and J. G. Hollowell, “Are detection and treatment of thyroid insufficiency in pregnancy feasible?” *Thyroid*, vol. 15, no. 1, pp. 44–53, 2005.

M. Rotondi, G. Mazzotti, F. Sorvillo et al., “Increased need for thyroxine during pregnancy due to thyroid dysfunction during early pregnancy,” *European Journal of Endocrinology*, vol. 151, no. 6, pp. 695–700, 2004.

M. Abalovich, G. Alcaraz, J. Kleiman-Rubinstein et al., “The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism,” *Thyroid*, vol. 20, no. 10, pp. 1175–1178, 2010.
[93] J. A. Loh, L. Wartofsky, J. Jonklaas, and K. D. Burman, “The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism,” *Thyroid*, vol. 19, no. 3, pp. 269–275, 2009.

[94] E. K. Alexander, E. Marqusee, J. Lawrence, P. Jarolim, G. A. Fischer, and P. R. Larsen, “Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism,” *New England Journal of Medicine*, vol. 351, no. 3, pp. 241–349, 2004.

[95] K. D. Burman, “Controversies surrounding pregnancy, maternal thyroid status, and fetal outcome,” *Thyroid*, vol. 19, no. 4, pp. 323–326, 2009.

[96] L. Yassa, E. Marqusee, R. Fawcett, and E. K. Alexander, “Thyroid hormone early adjustment in pregnancy (the THERAPY) trial,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 7, pp. 3234–3241, 2010.

[97] M. R. Haymart, “The role of clinical guidelines in patient care: thyroid hormone replacement in women of reproductive age,” *Thyroid*, vol. 20, no. 3, pp. 301–307, 2010.

[98] The American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, “Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,” *Thyroid*, vol. 21, no. 10, 2011.